Recursion secures largest deal yet with Roche, Genentech

Recursion continues its strategy to expand the reach of its drug discovery platform through partnerships, this time in a $150 million deal with Roche and Genentech focused on neurology and oncology. 

The deal is also the latest sign that phenotypic screening has made a comeback, fueled by improvements in cell models, high-content imaging and the computational tools needed to work backward from the phenotype to the biological mechanism and target.  ...